Helpful upcoming webinars this week

Three more upcoming webinars this week will deal with (a) the work-up of men with prostate cancer prostate cancer who progress after first-line therapy (such as surgery, radiation, etc.); (b) whether Gleason 6 disease should really be defined as “prostate cancer”; and (c) an update on the most current information related to the evaluation and management of men with prostate cancer appropriate for active surveillance. See below for details.

On Wednesday, July 28, at 7:00 to 8:30 pm Eastern, the Cancer Support Community and Prostate Cancer International will be presenting a webinar on the evaluation and work-up of men with prostate cancer who have actual or potentially progressive disease after their initial treatment. The featured speaker will be Prof. Judd Moul, MD, of Duke University and Duke Health in Durham, NC. He will be addressing current and potential new ways to properly evaluate such patients so that they can receive the most appropriate and relevant forms of follow-up care.

You will be able to take advantage of this educational webinar in three ways:

On Thursday, July 29, at 8:00 to 9:30 p,.m. Eastern, AnCan will be continuing its series of webinars on active surveillance with a debate entitled “Is Gleason 6 really prostate cancer?” The featured speakers for this debate will be Scott Eggener, MD, of the University of Chicago School of Medicine and Ming Zhou, MD, PhD, of Tufts Medical Center in Boston.

To register for this webinar, please click here.

Then on Saturday, July 31, at 12:00 (i.e., noon) to 1:30 pm Eastern, Active Surveillance Patients International is presenting a webinar on “The leading edge of active surveillance for patients and urologists“. The featured speaker will be Prof. Eric Klein, MD, of the Cleveland Clinic, who has been heavily involved in research into the application of new types of test that can be used in the assessment of risk for men who are pootential candidates for active surveillance.

To register for this webinar, please click here.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: